iSpecimen (NASDAQ:ISPC – Get Free Report) and CryoPort (NASDAQ:CYRX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.
Profitability
This table compares iSpecimen and CryoPort’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iSpecimen | -2,445.40% | -524.39% | -140.42% |
| CryoPort | -20.05% | -7.20% | -4.30% |
Volatility and Risk
iSpecimen has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.
Institutional & Insider Ownership
13.6% of iSpecimen shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 12.2% of iSpecimen shares are held by company insiders. Comparatively, 9.5% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares iSpecimen and CryoPort”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iSpecimen | $466,302.00 | 4.82 | -$10.49 million | ($56.44) | -0.02 |
| CryoPort | $176.18 million | 5.33 | $78.30 million | ($0.90) | -20.59 |
CryoPort has higher revenue and earnings than iSpecimen. CryoPort is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations for iSpecimen and CryoPort, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iSpecimen | 1 | 0 | 0 | 0 | 1.00 |
| CryoPort | 0 | 2 | 8 | 0 | 2.80 |
CryoPort has a consensus price target of $19.33, suggesting a potential upside of 4.34%. Given CryoPort’s stronger consensus rating and higher probable upside, analysts clearly believe CryoPort is more favorable than iSpecimen.
Summary
CryoPort beats iSpecimen on 12 of the 14 factors compared between the two stocks.
About iSpecimen
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
About CryoPort
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.
